{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132890","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.783552+00:00","generated_at":"2026-05-20T02:48:53.654834+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Trevi Therapeutics reports positive Phase 2b topline results for Haduvio in IPF chronic cough","bullets":["Primary endpoint met: 60.2% reduction in 24-hour cough frequency at 108 mg BID (p<0.0001) vs 16.9% placebo.","Statistically significant improvements on cough-severity NRS and E-RS:IPF Cough Subscale at 108 mg and 54 mg BID.","Discontinuation due to AEs similar between Haduvio (5.6%) and placebo (5.0%); safety profile consistent with prior trials.","Expects end-of-Phase 2 FDA meeting in H2 2025; plans Phase 2b trial in refractory chronic cough starting H1 2026.","Also plans to initiate clinical trial of Haduvio for non-IPF interstitial lung disease cough in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132890","json":"https://secwatch.observer/filing/0001193125-25-132890.json","markdown":"https://secwatch.observer/filing/0001193125-25-132890.md","text":"https://secwatch.observer/filing/0001193125-25-132890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525132890/0001193125-25-132890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000119312525132890/d949267d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:48:53.654834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}